Compare ASTL & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTL | VIR |
|---|---|---|
| Founded | 1902 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.0M | 1.5B |
| IPO Year | N/A | 2019 |
| Metric | ASTL | VIR |
|---|---|---|
| Price | $3.75 | $9.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $19.63 |
| AVG Volume (30 Days) | 1.2M | ★ 4.3M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $33.17 | $925.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.02 | $4.16 |
| 52 Week High | $7.25 | $10.91 |
| Indicator | ASTL | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 57.65 |
| Support Level | $3.54 | $4.64 |
| Resistance Level | $4.67 | $10.91 |
| Average True Range (ATR) | 0.28 | 0.61 |
| MACD | -0.12 | -0.05 |
| Stochastic Oscillator | 26.06 | 49.69 |
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.